A phase I clinical trial conducted by Chinese PLA General Hospital (NCT03747965) is currently evaluating the feasibility and safety of CRISPR-Cas9 mediated PD-1 gene-knockout CAR-T cells in patients with MSLN-positive multiple solid tumors, including esophageal cancer and gastric cancer. Here, MSLN is linked to esophageal cancer.